0091 - 755 - 4076518
HPV 16 & 18 Detection Kit

TRUPCR® HPV 16 & 18 Detection Kit

The TRUPCR® HPV High Risk (E6/E7) Kit is designed for the qualitative detection of DNA of High-Risk Human Papillomavirus (HPV) in clinical samples by using real time PCR. HPV infections are among the most common sexually transmitted infections. Most HPV infections have a benign clinical consequence and are cleared spontaneously. However, persistent HPV infection may result in progression to cervical cancer. More than one hundred different HPV genotypes have been identified, among which over forty infect mucosal and genital epithelia. Genital HPV genotypes are generally classified into high risk (HR) and low risk (LR) groups based on their carcinogenic potential. High-risk HPVs also called oncogenic HPVs, which have been confirmed to cause cancer, includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. And some HPVs are possibly carcinogenic to humans, like HPV 26, 53, 66, 70, 73 and 82, that be classified as high-risk or probably high-risk HPVs.

The TRUPCR® HPV High Risk (E6/E7) Kit is an RT-qPCR assay based on oligonucleotide hydrolysis principle which allows higher specificity and sensitivity of E6/E7 region by primer and probes specific for HPV 14 Genotypes (16/18/31/33/35/39/45/51/52/56/58/59/66 and 68) and simultaneous genotyping of 16 and 18.

  • HPV 16 & 18 Detection Kit

Key Features:

  • TaqMan Probe-Based Real-Time PCR Assay .
  • Covers HPV 14 Genotypes (16/18/31/33/35/39/45/51/52/56/58/59/66 and 68), and simultaneous genotyping of HPV 16 and 18 .
  • Based on E6/E7 oncoproteins which mediate the development of cervical cancer.
  • Endogenous internal control DNA which allows excluding unreliable results.
  • Higher sensitivity and specificity.
  • Extensively validated on Indian clinical samples.
  • Rapid, reliable, comprehensive and cost-effective test.
  • Easy work flow & compatible with various Real Time PCR instruments.

The role of HPVs in the etiology of cervical cancer is tightly correlated with the over expression of two oncogenes (E6 and E7) due to a specific opening in the E2 open reading frame in the integrated viral genome. The loss of the L1 gene and its impact on viral replication after integration could lead to relatively low viral loads, this suggests that the presence of the E6 and E7 proteins is a specific marker for high-grade lesions detection. Approximately 99.7% of cervical cancers are caused by high-risk HPV infection. Cervical cancer is the second-most frequent malignancy among women worldwide. Compared with cervical screening methods identifying cytological abnormalities, molecular tests that specifically detect the presence of HR HPV DNA in cervical cells can potentially increase sensitivity and cost effectiveness of cervical cancer screening programs.

Ordering Information:

3B1289 TRUPCR® HPV High Risk (E6/E7) Kit 48 Rxns
3B1290 TRUPCR® HPV High Risk (E6/E7) Kit 96 Rxns
Scroll to Top